A Registry of Treatment Adherence for Patients With Schizophrenia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2046 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-09-30

Study Completion Date

2006-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to assess demographic, treatment, and outcome data in schizophrenia patients receiving treatment with long-acting injectable, tablet, or liquid formulations of first generation (conventional) or second generation (atypical) antipsychotic medications.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Schizophrenia Treatment Adherence Investigation (STAI)

NCT01001481

Schizophrenia Schizoaffective Disorder

COMPLETED

Assessment of Schizophrenia Patients' Clinical Study Experiences

NCT05948111

Schizophrenia

NOT_YET_RECRUITING

Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia

NCT00406718

Schizophrenia Schizoaffective Disorder

COMPLETED NA

Brief Hospitalization for Schizophrenia: Strategies to Improve Treatment Outcome

NCT00018837

Schizophrenia Schizophrenic Disorder

COMPLETED NA

An Adherence Study of Antipsychotic Medication in Outpatients With Schizophrenia or Schizoaffective Disorder

NCT00861003

Schizophrenia Schizoaffective Disorder

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Recent studies have suggested the superior effectiveness of second generation (atypical) antipsychotic medications over first generation (conventional) antipsychotics in preventing relapse during the treatment of schizophrenia. It is estimated that a majority of patients with schizophrenia have difficulty adhering to the daily regimen of oral medications, and the use of long-acting injectable antipsychotics has been shown to increase compliance. This study includes both retrospective and prospective observations of the treatments and outcomes associated with antipsychotic drug therapy as well as characteristics of the patient population. The study is not product specific and includes patients using therapy with long-acting injectable, tablet, or liquid formulations of conventional or atypical antipsychotic medications. All patients who enroll in the study start treatment with a new antipsychotic medication, which is to be used according to the product labeling in the local country. Retrospective data, collected over a minimum of 12 months, include patient diagnosis, age, sex, history of treatment with antipsychotic medications, hospitalization, Clinical Global Impression of severity of disease (CGI-severity), Global Assessment of Functioning (GAF), and the reason for starting a new antipsychotic treatment. Prospective data, collected every 3 months over 2 years, are evaluated to assess the effectiveness of treatment and include the patient's adherence to antipsychotic medication, CGI-severity, GAF, and clinical deterioration of the patient's condition. The study investigator enters the data into a registry either electronically or on paper record forms. Safety assessments include the incidence, type and severity of adverse events throughout the prospective phase of the study. Atypical or conventional antipsychotics, as tablet, liquid or injectable formulations as prescribed

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Psychotic Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

001

antipsychotics

Intervention Type DRUG

as prescribed

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

antipsychotics

as prescribed

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients starting treatment with a new antipsychotic medication, in accordance with product labeling in the local country
* Permitted by their physician and by the patient to participate in a clinical trial

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No